Autologous platelet-rich fibrin (PRF) augmentation as an add-on therapy in deep surgical site infections (dSSIs) after instrumented spinal surgery: preliminary results of a single institution case series - Takeaways - MDSpire

Autologous platelet-rich fibrin (PRF) augmentation as an add-on therapy in deep surgical site infections (dSSIs) after instrumented spinal surgery: preliminary results of a single institution case series

  • By

  • Ioannis Vasilikos

  • Roland Roelz

  • Christoph Scholz

  • Boris Mizaikoff

  • Katerina Argiti

  • Watzlawick Ralf

  • Georgios-Christos Giagkos

  • Evangelos M. Fragkakis

  • Shahram Ghanaati

  • Jürgen Beck

  • Ulrich Hubbe

  • August 24, 2021

  • 0 min

Share

  • 1

    Deep surgical site infections (dSSIs) occur in up to 12% of post-operative spinal surgery cases, significantly impacting recovery and increasing socio-economic costs.

  • 2

    Standard management for dSSIs includes extensive debridement, drains, and targeted antibiotics, but reconstruction of soft tissue remains challenging.

  • 3

    Platelet-rich fibrin (PRF) is an autologous biomaterial that enhances wound healing and provides antimicrobial protection, used successfully in various surgical fields.

  • 4

    In a case series, 12 patients with persistent dSSIs underwent PRF augmentation after standard treatments failed, showing promising preliminary results.

  • 5

    The study highlights the potential of PRF as an effective add-on therapy for improving outcomes in patients with dSSIs following spinal surgery.

Original Source(s)

Related Content